Scleroderma lung: Initial forced vital capacity as predictor of pulmonary function decline
Open Access
- 27 July 2006
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 55 (4) , 598-602
Abstract
Objective: To determine the ability of initial forced vital capacity (FVC) of patients with scleroderma to predict subsequent pulmonary function deterioration.Methods: Data on 78 patients with scleroderma were retrospectively collected and analyzed. FVC (percent predicted), diffusing capacity for carbon monoxide (percent predicted), and various clinical and laboratory parameters were recorded. Pulmonary function decline (outcome) was defined as at least a 15‐point sustained decrease in FVC (percent predicted). Kaplan‐Meier analyses were performed separately for 60 patients initially assessed within the first 3 years from disease onset (group A) and 16 patients whose FVC values in the fourth or fifth year from disease onset were ascribed as baseline measurements (group B).Results: Based on baseline FVC, patients in each group were categorized into those with normal FVC (≥80% predicted) and those with decreased FVC (P = 0.04). Four patients with decreased baseline FVC developed respiratory failure (FVC P = 0.13). Clinical and laboratory parameters (age, male sex, baseline diffusion capacity, anti–topoisomerase I, or duration of Raynaud's phenomenon preceding skin manifestations) were not associated with pulmonary function decline.Conclusion: Measured within the first 3 years from disease onset, baseline FVC (percent predicted) may predict deterioration of pulmonary function in patients with scleroderma. Patients with normal pulmonary function at initial assessment are at low risk to develop considerable impairment of pulmonary function.Keywords
This publication has 27 references indexed in Scilit:
- Isolated pulmonary hypertension in sclerodermaInternal Medicine Journal, 2005
- Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosisAnnals of the Rheumatic Diseases, 2001
- Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 alleleAnnals of the Rheumatic Diseases, 2000
- Isolated diffusing capacity reduction in systemic sclerosisArthritis & Rheumatism, 1992
- Pulmonary manifestations of sclerodermaJournal of Thoracic Imaging, 1992
- D‐penicillamine treatment of lung involvement in patients with systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1987
- The effect of D‐penicillamine on pulmonary findings in systemic sclerosisArthritis & Rheumatism, 1985
- Clinical and Demographic Predictors of Loss of Pulmonary Function in Systemic SclerosisMedicine, 1984
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980
- Serial pulmonary function tests in progressive systemic sclerosis.Thorax, 1979